Latest Capital Allocation News

LG Energy Solution has converted its entire US$250 million convertible note into equity in Liontown, acquiring an 8% stake and simplifying the lithium miner’s capital structure.

Betr Entertainment Limited reported a robust 25% headline turnover growth in Q2 FY26 despite a $13.2 million EBITDA loss in H1 due to customer-friendly racing outcomes and strategic investments. The company targets a positive EBITDA turnaround in H2 FY26 and FY27, supported by organic growth, Sky Racing integration, and a new share buyback program.

betr Entertainment reported a $13.2 million EBITDA loss in H1 FY26 due to strategic investments and favourable customer outcomes but projects a strong rebound with a $13-19 million EBITDA target for FY27.

Horizon Oil reported an 18% rise in production and sales volumes in Q2 FY26, driven by its first full quarter of Thailand asset output. The company also maintained strong cashflow, paid a final FY25 dividend, and secured a long-term gas supply agreement in Australia’s Northern Territory.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Champion Iron Limited reported robust Q3 FY2026 results with record sales and ongoing progress on its DRPF project, while launching a significant acquisition offer for Rana Gruber.

Whitehaven Coal reported a strong December quarter with a 21% rise in production and improved metallurgical coal prices, underpinning a solid first half of FY26. The company also advanced key development projects while maintaining disciplined cost management.

Torque Metals is advancing its Paris Gold Camp project in Western Australia, moving from exploration to development readiness with a 250,000-ounce gold resource and an aggressive drilling program.

Ramelius Resources reported a robust December 2025 quarter with solid gold production, strong cash flow, and significant progress on major projects including Never Never and Rebecca-Roe.

Metals X delivered near-record tin output at its Renison operation in Q4 2025, driving a doubling of EBITDA amid improved efficiencies and strong capital progress. The company also advanced its Rentails project and maintained robust cash reserves.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Streamplay Studio Limited has reported a third consecutive cash-flow positive quarter, driven by the blockbuster launch of Winter Burrow and key Tier-1 platform partnerships including Amazon. The company’s diversified publishing and subscription model underpins a robust financial position heading into 2026.